Melanotan I — reference
An alpha-MSH analogue (afamelanotide) that stimulates melanin production; FDA-approved as an implant for a rare light-sensitivity disorder.
Regulatory status
FDA-Approved (labeled use). FDA-approved as SCENESSE for erythropoietic protoporphyria — a rare condition. The injectable peptide sold online for tanning is not that product and is not approved.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~1 hour (as solution injection); differs from the FDA-approved slow-release implant form (afamelanotide/Scenesse). Don't conflate implant duration with plasma half-life if you cite the FDA-approved form.
This figure is tagged Limited data in our evidence system. The available data does not support a confident single figure, so this entry is flagged accordingly. Read any curve built from it as illustrative only. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Melanotan I FDA-approved?
What is the half-life of Melanotan I?
How reliable is that half-life figure?
What cautions are associated with Melanotan I?
Does Peptide Plug publish dosing for Melanotan I?
Does Peptide Plug sell Melanotan I?
Related tools
Free, no account required.
The public research page intentionally does not publish dosing. Pro subscribers can open the separate Protocol Library for structured indication, frequency, duration, notes, and review-first Cycle Builder import when a matching reference is available.
View Protocol Reference